Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Interest Expenses (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Interest Expenses for 13 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses rose 17.63% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Dec 2025, down 24.48% year-over-year, with the annual reading at $9.0 million for FY2025, 16.14% down from the prior year.
  • Interest Expenses hit $2.2 million in Q4 2025 for Coherus Oncology, down from $2.3 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $10.6 million in Q4 2023 to a low of $1.9 million in Q4 2024.
  • Historically, Interest Expenses has averaged $5.8 million across 5 years, with a median of $5.8 million in 2021.
  • Biggest five-year swings in Interest Expenses: skyrocketed 823.95% in 2021 and later tumbled 81.99% in 2024.
  • Year by year, Interest Expenses stood at $5.8 million in 2021, then skyrocketed by 62.01% to $9.4 million in 2022, then rose by 13.15% to $10.6 million in 2023, then crashed by 81.99% to $1.9 million in 2024, then grew by 17.63% to $2.2 million in 2025.
  • Business Quant data shows Interest Expenses for CHRS at $2.2 million in Q4 2025, $2.3 million in Q3 2025, and $2.3 million in Q2 2025.